Drug
Batefenterol clinical trials
Also written GSK961081.
- studies test it
- 10
- open now
- 0
- in phase 3
- 0
- first study started
- 2005
How studies write it
Studies that test it under each name
Name
Development codes
Combined with it in one product
Studies by the year they started
10 studies that test it; most in 2007 (2)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2007 | 2 |
| 2008 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 0
Often tested with
Tested in the same studies.
Fluticasone furoate (2) · Propranolol (1) · GSK573719 (1) · Vilanterol (1)
Studies
Open first, then newest update. How each study uses batefenterol is read from its arms, and is right about nine times in ten.
Testing it · 10
- Succinate Salt Version of GSK961081 for Healthy VolunteersCompletedPhase 1Theravance BiopharmaNCT00550225Written as GSK961081
- A Phase 1 (Ph1), Single Dose (SD), GSK961081 Absorption, Distribution, Metabolism, and Excretion (ADME) Study in Healthy SubjectsCompletedPhase 1Theravance BiopharmaNCT02663089Written as [14C]-GSK961081 oral solution
- Study of GSK961081 in Healthy Volunteer SubjectsCompletedPhase 1Theravance BiopharmaNCT00887406Written as GSK961081 15mcg SD
- A Study to Investigate the Pharmacology of a Dual Pharmacophore in Healthy VolunteersCompletedPhase 1Theravance BiopharmaNCT00687700Written as GSK961081
- Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary DiseaseCompletedPhase 2GlaxoSmithKlineNCT02573870Written as Batefenterol + Fluticasone Furoate
- Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedPhase 2GlaxoSmithKlineNCT02570165Written as Batefenterol
- An Investigation of the Pharmacokinetics of GSK961081 and Fluticasone Propionate in Healthy VolunteersCompletedPhase 1GlaxoSmithKlineNCT01449799Written as GSK961081 800 microgram dose
- Study to Determine the Pharmacokinetics of GSK961081 and Fluticasone Furoate When Administered Alone or in CombinationCompletedPhase 1GlaxoSmithKlineNCT02064504Written as GSK961081
- A 2 Part Study Examining Doses Of GSK961081 In Healthy Volunteers And Then In COPD PatientsCompletedPhase 2GlaxoSmithKlineNCT00478738Written as GSK961081
- A 4-week Dose-Ranging, Dose-Interval, Efficacy, Safety and Tolerability Study of GSK961081 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedPhase 2GlaxoSmithKlineNCT01319019Written as GSK961081
Codes
What other systems call batefenterol · ClinicalTrials.gg INT006485
- UNII (FDA) 1IAT42T80TBATEFENTEROLConfirmed FDA, Wikidata
- Wikidata Q27252454batefenterolConfirmed FDA, Wikidata
- NCI Thesaurus C166503BatefenterolOne source FDA
- DrugBank DB12526One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 1IAT42T80T | BATEFENTEROL | Confirmed FDA, Wikidata |
| Wikidata | Q27252454 | batefenterol | Confirmed FDA, Wikidata |
| NCI Thesaurus | C166503 | Batefenterol | One source FDA |
| DrugBank | DB12526 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.